Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma
5 意见
• 08/09/23
0
0
嵌入
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论